The role of JAK2 inhibitors like ruxolitinib and fedratinib has been studied in patients with myelofibrosis and myeloproliferative neoplasms (MPNs) that consistently exhibit dysregulation of the JAK1/JAK2 pathway [27–29]. The gene discussed is JAK2; the disease is myelofibrosis.